EMEL BAŞAR
(İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İstanbul, Türkiye)
CEYHUN ARICI
(Boş)
Yıl: 2016Cilt: 46Sayı: 6ISSN: 1300-0659 / 2147-2661Sayfa Aralığı: 282 - 290Türkçe

66 7
Oftalmolojide Botulinum Nörotoksini Kullanımı
Botulinum nörotoksini (BoNT), insanlarda tedavi amaçlı ve kırışıklıkların önlenmesinde kozmetik amaçlı kullanılmaya başlanmış olan ilk biyolojik toksindir. Uygun kullanımda kas kontraksiyon gücünü ve/veya salgı bezi sekresyonunu azaltır. BoNT'nin en sıklıkla kullanıldığı alan üst yüz bölgesidir [glabella, alın, kaşlar ve lateral kantus kırışıklıkları (kaz ayakları)]. Estetikte kırışıklıklara neden olan kasları gevşeterek kalıcı olmayan bir düzelmeye neden olur. BoNT değişik oftalmik hastalıklarda yaygın olarak kullanılmaktadır. BoNT'nin etkisi geçicidir; ama tekrar eden enjeksiyonlardan sonra tedavi amaçlı etkinlik süresi genellikle uzar. Tedavi genellikle iyi tolere edilmektedir. Tedavi ile ilişkili komplikasyonlar ve yan etkiler nadir ve geçicidir. Komplikasyonlar komşu kas gruplarında meydana gelen zayıflama (kemodenervasyon), immünolojik mekanizmalar ve enjeksiyon tekniklerine bağlı olarak gelişmektedir. Bilimsel literatür değerlendirilerek BoNT'nin oftalmoloji ile ilgili hastalıklarda güncel tedavi endikasyonları, dozları, komplikasyonları ve kontrendikasyonları incelenmiştir. Bunlar; estetik amaçlı, şaşılık, blefarospazm, hemifasiyal spazm, göz kapak retraksiyonu, entropium, lakrimal hipersekresyon sendromu ve fasiyal paralizidir.
Fen > Tıp > Göz Hastalıkları
DergiDerlemeErişime Açık
  • Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. Indian J Med Res. 2010;132:489-503.
  • Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-927.
  • Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17:21-25.
  • Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52:13-31.
  • Goodman G. Botulinum toxin for the correction of hyperkinetic facial lines. Australas J Dermatol. 1998;39:158-163.
  • Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol. 1999;38:641-655.
  • Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol. 1996;34:788-797.
  • de Maio M. Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders. Expert Opin Biol Ther. 2008;8:791-798.
  • Dowell VR, Jr. Botulism and tetanus: selected epidemiologic and microbiologic aspects. Rev Infect Dis. 1984;6(Suppl 1):202-207.
  • Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7:31-39.
  • Erickson BP, Lee WW, Cohen J, Grunebaum LD. The role of neurotoxins in the periorbital and midfacial areas. Facial Plast Surg Clin North Am. 2015;23:243-255.
  • Kane M, Donofrio L, Ascher B, Hexsel D, Monheit G, Rzany B, Weiss R. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol. 2010;9:7-22.
  • Trindade De Almeida AR, Secco LC, Carruthers A. Handling botulinum toxins: an updated literature review. Dermatol Surg. 2011;37:1553-1565.
  • Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res. 2009;15:224-231.
  • Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg. 2008;10:273-279.
  • Hexsel D, Rutowitsch MS, de Castro LC, do Prado DZ, Lima MM. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35:933-939.
  • Alam M, Yoo SS, Wrone DA, White LE, Kim JY. Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation. J Am Acad Dermatol. 2006;55:272-275.
  • Stephan S, Wang TD. Botulinum toxin: clinical techniques, applications, and complications. Facial Plast Surg. 2011;27:529-539.
  • Guerrissi JO. Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow's feet. Plast Reconstr Surg. 2003;112:161-163.
  • Kane MA. Classification of crow's feet patterns among Caucasian women: the key to individualizing treatment. Plast Reconstr Surg. 2003;112:33-39.
  • Fagien S. Botulinum toxin type A for facial aesthetic enhancement: role in facial shaping. Plast Reconstr Surg. 2003;112:6-18.
  • Park MY, Ahn KY. Botulinum toxin a for the treatment of hyperkinetic wrinkle lines. Plast Reconstr Surg. 2003;112:148-150.
  • Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg. 2003;29:468-476.
  • Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20:109-120.
  • Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999;103:701-713.
  • Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, Botox Glabellar Lines IISG. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-1098.
  • Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, Group BGLIS. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
  • Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33:51-59.
  • Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB, Reloxin Investigational G. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo- controlled study. Plast Reconstr Surg. 2009;124:1619-1629.
  • Rzany B, Dill-Muller D, Grablowitz D, Heckmann M, Caird D, German- Austrian Retrospective Study G. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg. 2007;33:18-25.
  • Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297-1303.
  • Maas CS, Kim EJ. Temporal brow lift using botulinum toxin A: an update. Plast Reconstr Surg. 2003;112:109-112.
  • Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg. 2000;105:1129-1135.
  • Uygur S, Eryilmaz T, Bulam H, Yavuzer R, Latifoglu O. The quantitative effect of botulinum toxin A over brow height. J Craniofac Surg. 2013;24:1285- 1287.
  • Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 1993;119:1018-1022.
  • Terzioğlu A, Tuncalı D, Barutçu AY, Başer NT, Aslan G. Botulinum toxin A: Cosmetic Use and literature review. Türk Plast Rekonstr ve Est Cer Derg. 2005;13:185-190.
  • Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N, Botox Facial Aesthetics Study T. Double-blind, randomized, placebo-controlled, dose- response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257-262.
  • Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose- ranging study. Dermatol Surg. 2009;35:1478-1486.
  • Prager W, Wissmuller E, Kollhorst B, Boer A, Zschocke I. [Treatment of crow's feet with two different botulinum toxin type A preparations in split- face technique]. Hautarzt. 2011;62:375-379.
  • Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001;108:208- 214.
  • Crouch ER. Use of botulinum toxin in strabismus. Curr Opin Ophthalmol. 2006;17:435-440.
  • Benabent EC, Garcia Hermosa P, Arrazola MT, Alio y Sanz JL. Botulinum toxin injection without electromyographic assistance. J Pediatr Ophthalmol Strabismus. 2002;39:231-234.
  • Flanders M, Tischler A, Wise J, Williams F, Beneish R, Auger N. Injection of type A botulinum toxin into extraocular muscles for correction of strabismus. Can J Ophthalmol. 1987;22:212-217.
  • Lennerstrand G, Nordbo OA, Tian S, Eriksson-Derouet B, Ali T. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand. 1998;76:27-27.
  • Petitto VB, Buckley EG. Use of botulinum toxin in strabismus after retinal detachment surgery. Ophthalmology. 1991;98:509-512.
  • Gursoy H, Basmak H, Sahin A, Yildirim N, Aydin Y, Colak E. Long-term follow-up of bilateral botulinum toxin injections versus bilateral recessions of the medial rectus muscles for treatment of infantile esotropia. J AAPOS. 2012;16:269-273.
  • McNeer KW, Tucker MG, Guerry CH, Spencer RF. Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A. J Pediatr Ophthalmol Strabismus. 2003;40:288-292.
  • Başar E. [Esotropia]. [Eye diseases in children]. İstanbul: Martı Ofset 2009:.177-182.
  • Tengtrisorn S, Treyapun N, Tantisarasart T. Botulinum A toxin therapy on esotropia in children. J Med Assoc Thai. 2002;85:1189-1197.
  • Ruiz MF, Moreno M, Sanchez-Garrido CM, Rodriguez JM. Botulinum treatment of infantile esotropia with abduction nystagmus. J Pediatr Ophthalmol Strabismus. 2000;37:196-205.
  • Campos EC, Schiavi C, Bellusci C. Critical age of botulinum toxin treatment in essential infantile esotropia. J Pediatr Ophthalmol Strabismus. 2000;37:328- 332.
  • Metz HS, Dickey CF. Treatment of unilateral acute sixth-nerve palsy with botulinum toxin. Am J Ophthalmol. 1991;112:381-384.
  • Yabaş Ö, Ziylan Ş, Zorlutuna N, Doruga İ. Botulinum toxin in acute sixth nerve palsy. Turk J Ophthalmol. 2006;36:276-280.
  • Başar E, Oğuz H, Akova N, Özkan N, Mirzataş Ç. Comparison of Jensen's procedure combined with recession of antagonist medial rectus muscle or botulinum toxin injection into antagonist medial rectus muscle: Outcome in a patient with bilateral sixth nevre palsy. Ann Med Sci 2005;14:8-11.
  • İncili B, ÖnaL S, Demirtaş S, Öğüt MS. Boyulinum toxin chemodenervation combined with transposition surgery for chronic sixth nerve palsy: A presentation of three cases. Turk J Ophthalmol. 2006;36:321-325.
  • Sener EC, Sanac AS. Efficacy and complications of dose increments of botulinum toxin-A in the treatment of horizontal comitant strabismus. Eye (Lond). 2000;14:873-878.
  • Han SH, Lew H, Jeong CW, Lee JB. Effect of botulinum toxin A chemodenervation in sensory strabismus. J Pediatr Ophthalmol Strabismus. 2001;38:68-71.
  • Dawson EL, Marshman WE, Lee JP. Role of botulinum toxin A in surgically overcorrected exotropia. J AAPOS. 1999;3:269-271.
  • Ozkan SB, Kir E, Dayanir V, Dundar SO. Botulinum toxin A in the treatment of adherence syndrome. Ophthalmic Surg Lasers Imaging. 2003;34:391-395.
  • Wu X, Lin N, Ai LK, Wang JH, Yan LJ. [The application of botulinum toxin A in the treatment of restrictive strabismus in thyroid associated ophthalmopathy]. Zhonghua Yan Ke Za Zhi. 2006;42:1063-1067.
  • Tomsak RL, Remler BF, Averbuch-Heller L, Chandran M, Leigh RJ. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol. 1995;119:489-496.
  • Carruthers J. The treatment of congenital nystagmus with Botox. J Pediatr Ophthalmol Strabismus. 1995;32:306-308.
  • Başar E, Pazarlı H, Kayıran A. Chemical denervation for the treatment of functional blindness due to essential blepharospasm. Cerrahpaşa J Med 2003;34:24-27.
  • Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767-772.
  • Lee MS, Johnson M, Harrison AR. Gender differences in benign essential blepharospasm. Ophthal Plast Reconstr Surg. 2012;28:169-170.
  • Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol. 1996;41:51-65.
  • Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988;95:1529- 1534.
  • Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol. 2002;249:64-68.
  • Streitova H, Bares M. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg. 2014;114:285-291.
  • Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol. 2013;156:173-177.
  • Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254-261.
  • Aydın P, Çakmakçı Ş. Treatment of blepharospasm and hemifacial spasm with botulinum- a toxin. Türkiye Klinikleri J Ophthalmol. 2000;9:122-126.
  • Yüksel D. The Use of Botulinum Toxin in the Treatment of Blepharospasm and Hemifacial Spasm: Review. Turkiye Klinikleri J Ophthalmol. 2009;18:256-263.
  • Vogt T, Lussi F, Paul A, Urban P. [Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A]. Nervenarzt. 2008;79:912-917.
  • Gonnering RS. Treatment of hemifacial spasm with botulinum A toxin. Results and rationale. Ophthal Plast Reconstr Surg. 1986;2:143-146.
  • Çiftçi F, Karadayı K, Yıldız T, Akın T, Yıldırım Y, Gülecek O. Effectiveness of chemical denervation with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm. Turk J Ophthalmol. 2005;35:84-92.
  • Yağcı A, Köse S, Kayıkçıoğlu Ö, Pamukçu K. Application of Botulismus-toxin in patients with essential blepharospasm. MN Oftalmoloji 1998;5:138-140.
  • Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988;95:1529- 1534.
  • Wutthiphan S, Kowal L, O'Day J, Jones S, Price J. Diplopia following subcutaneous injections of botulinum A toxin for facial spasms. J Pediatr Ophthalmol Strabismus. 1997;34:229-234.
  • Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol. 1994;22:255- 260.
  • Flanders M, Chin D, Boghen D. Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol. 1993;33:316-319.
  • Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry. 1998;64:751-757.
  • Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol. 2009;16:392-398.
  • Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 1995;18:720-729.
  • Gill HS, Kraft SP. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci. 2010;37:631-636.
  • Akdemir MO, Uğurbaş CS, Uğurbaş SH. Long-term effect of botulinum toxin in the treatment of benign essential blepharospasm and hemifacial spasm. Turk J Ophthalmol 2015;45:1-4.
  • Morgenstern KE, Evanchan J, Foster JA, Cahill KV, Burns JA, Holck DE, Perry JD, Wulc AE. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthal Plast Reconstr Surg. 2004;20:181-185.
  • Hekimhan PK. Botulinum toxin applications in periocular pathologies. Türkiye Klinikleri J Surg Med Sci 2007;3:56-61.
  • Kaynak P, Karabulut ÖG, Öztürker C, Yıldırım Y, Alagöz N, Akar S, Gökyiğit B, Demirok A. Upper eyelid retraction management with subconjunctival ınjection of botulinum toxin type a in patients with thyroid eye disease. MN Oftalmoloji 2013;20:272-278.
  • Salour H, Bagheri B, Aletaha M, Babsharif B, Kleshadi M, Abrishami M, Bagheri A. Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease. Orbit. 2010;29:114-118.
  • Deka A, Saikia SP. Botulinum toxin for lower lid entropion correction. Orbit. 2011;30:40-42.
  • Baranano DE, Miller NR. Long term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome. Br J Ophthalmol. 2004;88:588-589.
  • Nava-Castaneda A, Tovilla-Canales JL, Boullosa V, Tovilla-y-Pomar JL, Monroy-Serrano MH, Tapia-Guerra V, Garfias Y. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthal Plast Reconstr Surg. 2006;22:453-456.
  • Wabbels B, Forl M. [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction]. Ophthalmologe. 2007;104:771-776.
  • Naik MN, Gangopadhyay N, Fernandes M, Murthy R, Honavar SG. Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox) to induce temporary ptosis for corneal protection. Eye (Lond). 2008;22:1132-1136.
  • Yucel OE, Arturk N. Botulinum toxin-A-induced protective ptosis in the treatment of lagophthalmos associated with facial paralysis. Ophthal Plast Reconstr Surg. 2012;28:256-260.
  • Tsui JK. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 1996;72:13- 24.
  • Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33:51-59.
  • Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB, Reloxin Investigational G. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo- controlled study. Plast Reconstr Surg. 2009;124:1619-1629.
  • Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, Group BGLIS. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
  • Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol. 1996;41:51-65.
  • Ricci LH, Navajas SV, Carneiro PR, Soderberg SA, Ferraz CA. Ocular adverse effects after facial cosmetic procedures: a review of case reports. J Cosmet Dermatol. 2015;14:145-151.
  • Carruthers J, Carruthers A. Complications of botulinum toxin type A. Facial Plast Surg Clin North Am. 2007;15:51-54.
  • Zheng L, Azar D. Angle-closure glaucoma following periorbital botulinum toxin injection. Clin Experiment Ophthalmol 2014;42:690-693.
  • Corridan P, Nightingale S, Mashoudi N, Williams AC. Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol. 1990;74:309-310.
  • Liu M, Lee HC, Hertle RW, Ho AC. Retinal detachment from inadvertent intraocular injection of botulinum toxin A. Am J Ophthalmol. 2004;137:201- 202.
  • Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407-415.
  • Rohrich RJ, Janis JE, Fagien S, Stuzin JM. The cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;112:177-188.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.